BioVie Inc. (BIVI)

Market Cap	26.85M
Revenue (ttm)	n/a
Net Income (ttm)	-43.27M
Shares Out	54.92M
EPS (ttm)	-1.17
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	774,237
Open	0.504
Previous Close	0.505
Day's Range	0.469 - 0.510
52-Week Range	0.445 - 8.690
Beta	1.21
Analysts	Buy
Price Target	8.00 (+1,536.33%)
Earnings Date	May 10, 2024

About BIVI

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer'...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 18
• Stock Exchange: NASDAQ
• Ticker Symbol: BIVI

Analyst Forecast

According to 2 analysts, the average rating for BIVI stock is "Buy." The 12-month stock price forecast is $8.0, which is an increase of 1,536.33% from the latest price.

Price Target

$8.0

(1,536.33% upside)

Analyst Consensus: Buy